 |
인쇄하기
취소
|
Ildong to co-develop GLP-1 fusion protein formulations with Genexine
Ildong Pharm and Genexine Co., a drug development biotech, entered into a collaboration agreement by signing a contract of the Product co-development.
The contract encompasses co-commercialization of GLP-1 (glucagon-like peptide-1) fusion protein formulation using Genexine's proprietary hybrid Fc-fusion technology, one of the technologies for 2nd generation protein drugs. It can prolong the...
The contract encompasses co-commercialization of GLP-1 (glucagon-like peptide-1) fusion protein formulation using Genexine's proprietary hybrid Fc-fusion technology, one of the technologies for 2nd generation protein drugs. It can prolong the...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.